Hemostatic Findings in Ascitic Fluid: A Cross-Sectional Study in 70 Dogs

A. Zoia, M. Drigo, C.J. Pick, P. Simioni, and M. Cadin

Background: Ascitic fluids of horses and humans have fibrinolytic activity, independent of the underlying mechanism of fluid formation.

Objective: To determine whether coagulation and fibrinogenolytic/fibrinolytic activity (ie, low fibrinogen and increased fibrin–fibrinogen degradation products [FDPs], D-dimer, or both) occur in all types of ascitic fluid in dogs.

Animals: A total of 70 client-owned dogs with ascites.

Methods: In this cross-sectional study, dogs were categorized based on the pathophysiology of fluid formation into 4 groups: transudates due to decreased osmotic pressure, transudates due to increased hydrostatic pressure, exudates, and hemorrhagic ascites. Fibrinogen, FDPs, and D-dimer concentrations were measured and then compared in both ascitic fluid and plasma.

Results: Ten dogs had transudates due to decreased colloid osmotic pressure, 18 had transudates due to increased hydrostatic pressure, 13 had exudates, and 29 had hemorrhagic ascites. Ascitic fibrinogen concentrations (n = 70) were significantly lower (median = 59 mg/dL; range: 59–122 mg/dL) than those in the plasma (median = 168 mg/dL; range: 59–879 mg/dL; P < .0001). Ascitic FDPs concentrations (n = 70) were significantly higher (<5 μg/mL: 3/70 dogs, ≥5 to <20 μg/mL: 11/70 dogs, ≥20 μg/mL: 56/70 dogs) than those in the plasma (<5 μg/mL: 17/70 dogs, ≥5 to <20 μg/mL: 28/70 dogs, ≥20 μg/mL: 25/70 dogs; P < .0001). Ascitic D-dimer concentrations (n = 70) were significantly higher (median = 3.98 μg/mL; range: 0.02–9.19) than those in the plasma (median = 0.11 μg/mL; range: 0.01–4.08; P < .0001). Analysis of the data for each of the 4 different types of ascites showed similar results to those of all the data analyzed together.

Conclusions and Clinical Importance: Ascitic fluid of dogs has evidence of coagulation activation and fibrinogenolytic/fibrinolytic activity and that this phenomenon occurs independent of the underlying mechanism that leads to the formation of ascites.

Key words: Ascites; Canine; Fibrinogenolyis; Fibrinolysis.

Abbreviations:

- CHF: congestive heart failure
- COP: colloid osmotic pressure
- FDPs: fibrin–fibrinogen degradation products
- PHP: primary hyperfibrinogenolysis
- TNCC: total nucleated cell count
- TP: total protein

Starling forces and form across a normal peritoneal surface.1,3,4

Causes of transudative ascites in animals include diseases that cause increased venous hydrostatic pressure with portal hypertension (eg, congestive heart failure [CHF], liver diseases) or decreased colloid osmotic pressure (COP) (eg, protein losing enteropathy, protein losing nephropathy, or severe hepatic failure).2 Hemorrhagic ascites occurs secondary to the pathological accumulation of blood in the peritoneal cavity. In animals, hemorrhagic ascites occurs secondary to trauma, spontaneous ruptures of pathological organs, and coagulopathy.2

With the exception of the hemorrhagic ascites, in which the abdominal fluid accumulates due to rupture of blood vessels or secondary to clotting disorders, all the other ascitic fluids originate secondary to exudation or ultrafiltration of plasma. All ascitic fluid contains proteins involved in coagulation in an environment where the actions of these proteins are not well regulated due to the lack of other constituents of the hemostatic system (eg, platelets, vascular endothelium). In 3 human studies with different panels of coagulation assays, all the ascitic fluids evaluated were shown to
have fibrinolytic activity, independent of the underlying mechanism of formation.\(^5\)\(^7\) In 2 of these studies, patients with ascites secondary to liver cirrhosis were enrolled and the findings suggested that the inherently fibrinolytic activity of the ascites may contribute to the systemic hyperfibrinolytic state typically seen in advanced liver disease.\(^6\)\(^7\) Also horses with any type of pathological abdominal effusion have a significantly higher ascitic D-dimer concentration than plasma concentration, suggesting there is fibrinolytic activity within the effusion.\(^8\)

The objective of the cross-sectional study reported here was to determine whether coagulation and fibrinogenolytic/fibrinolytic activity (ie, low fibrinogen and increased fibrin–fibrinogen degradation products [FDPs] or D-dimer, or low fibrinogen and increased FDPs and D-dimer) occurs in any type of canine ascitic fluid.

### Materials and Methods

#### Animals

In this study, 219 dogs with abdominal effusion of any origin, as confirmed by abdominal ultrasonography, were studied. The dogs consecutively presented to the San Marco Veterinary Clinic from September 2011 to January 2013. In 81 of these dogs, ascitic fluid collection was performed at the time of presentation, and concurrently (±2 hours), a cephalic (for medium or large size dogs) or (for small size dogs) jugular venous blood sample was taken for laboratory investigation. Only dogs, in which the pathophysiologic cause for the abdominal effusion formation was established and there was a complete medical record, including history and results of physical examination, CBC (including blood smear examination), serum biochemistry analysis, coagulation profile analysis, urinalysis, ascitic fluid analysis, and additional diagnostic tests necessary to determine a diagnosis, were included in the study. Dogs were excluded from further analysis if they had a concomitant pleural effusion at the time of presentation to keep the studied population as homogeneous as possible. Dogs were also excluded from further analysis if they had received treatment with plasma, plasma derivate or anticoagulant treatment/intoxication within 30 days before study enrollment.

#### Ascitic Fluid Classification

Abdominal effusions were classified based on the pathophysiologic of its formation. According to Starling’s law,\(^9\) transudates were the ascites resulting from decreased COP (group 1) or increased hydrostatic pressure (group 2), and exudates were the ascites resulting from increased vascular permeability (group 3). Finally, the ascitic fluids resulting from blood vessel rupture were classified as hemorrhagic effusions (group 4). The diagnosis of the disease that caused the ascites was used as the gold standard for establishing the pathophysiology of abdominal fluid formation.

Transudates resulting from decreased COP included the effusions from dogs with hypoproteinemia due to protein losing enteropathy, protein losing nephropathy, or severe hepatic failure. Hypoproteinemia, and not hypoalbuminemia, was used as an aid for the indirect identification of decreased COP because in sick human patients a poor correlation exists between COP and serum albumin concentration.\(^10\) and in healthy dogs COP correlates better with serum total protein (TP).\(^11\)\(^12\) Transudates resulting from increased hydrostatic pressure included the effusions from dogs with right-sided CHF or other diseases that caused portal hypertension. Exudates were the effusions from dogs with neoplasia that directly involved the abdominal wall or the intra-abdominal organs’ serosal surfaces, septic and nonseptic peritonitis, or bile peritonitis. Hemorrhagic ascites were the effusions resulting from iatrogenic, traumatic, or spontaneous intra-abdominal bleeding.

### Ascitic Fluid Fibrinogen, FDPs, D-Dimer, TP, Hematocrit, and Total Nucleated Cell Count (TNCC) Analysis

The fibrinogen, FDPs, and D-dimer concentrations were measured in all the ascitic fluids. A whole ascitic sample was collected from each dog via ultrasonographic-guided abdominocentesis. Ascitic samples were immediately placed in plastic tubes containing K\(_3\)-EDTA for the determination of hematocrit and TNCC, plain tubes for the determination of TP (with an automated chemistry analyzer),\(^13\) and plastic tubes containing 3.2% sodium citrate (final ratio of volume of anticoagulant to volume of ascitic fluid, 1 : 9)\(^8\) for measurement of the coagulation variables. Tubes containing sodium citrate were centrifuged at 1,500 × g for 5 minutes. Then, the supernatant of the ascitic fluid was harvested, and fibrinogen, FDPs, and D-dimer concentrations were determined within 1 hour after ascitic sample collection. A board certified clinical pathologist (MC) performed the cytological examinations of all of the ascitic fluids.

#### Plasma Fibrinogen, FDPs, and D-Dimer Analysis

Plasma concentrations of fibrinogen, FDPs, and D-dimer were determined in all dogs. A whole blood sample (3.5 mL) was collected from each dog via cephalic (for medium or large size dogs) or jugular venipuncture (for small size dogs). Blood samples were immediately placed in plastic tubes containing 3.2% sodium citrate (final ratio of volume of anticoagulant to volume of blood, 1 : 9)\(^8\) for measurement of all the coagulation variables. Tubes containing sodium citrate were centrifuged at 1,500 × g for 5 minutes. Then, the plasma was harvested, and a coagulation profile analysis was performed within 1 hour after blood sample collection. Fibrinogen concentrations were determined via quantitative assays\(^14\) with an automated analyzer.\(^2\) The detection limit for fibrinogen concentration was 60 mg/dL; if a value was below the detection limit, the value was entered into the data sheet as 59 mg/dL for the statistical analysis. The plasma concentrations of FDPs were determined with a semiquantitative plasma latex agglutination kit\(^14\) that was validated\(^13\) for use with canine blood. Plasma D-dimer concentrations were determined with a validated\(^14\) immunoturbidimetric quantitative assay\(^8\) with an automated chemistry analyzer.\(^2\)

#### Statistical Analysis

Normality of data was assessed with the Kolmogorov–Smirnov test. Fibrinogen, FDPs, and D-dimer concentrations were compared between asctic fluid and venous blood via the Wilcoxon signed-rank test (fibrinogen and D-dimer), and Pearson’s chi-square test (FDPs). The same analysis by the same statistical tests was applied when the data were analyzed within the 4 groups. Finally, the correlation between asctic TP and asctic D-dimer was calculated by rank correlation by means of the Spearman ρ coefficient. For all statistical analyses, values of P < .05 were considered significant.

#### Results

##### Animals and Ascitic Fluid Classification

Of the 81 dogs from which ascitic fluid and venous blood samples were taken at the time of presentation, 11 dogs (one due to rodenticide exposure, 8 with
concurrent pleural effusion, and 2 due to a lack of a clear pathophysiological cause for the abdominal fluid formation) were excluded. The remaining 70 dogs were included in the study. There were 49 males (44 sexually intact and 5 neutered) and 21 females (13 sexually intact and 8 spayed). The mean age of these dogs was 8.6 ± 3.4 years (range, 1–15 years). Eighteen of the dogs were crossbred, and 52 were purebred (13 German shepherds, 5 Cane Corsos, 5 Labrador retrievers, 3 boxers, 3 cocker spaniels, 3 Yorkshire terriers, 2 Maltese, 2 Siberian huskies, and 1 of each of the following 16 breeds: American Staffordshire terrier, beagle, Bernese mountain dog, bichon frise, border collie, Doberman, fox terrier, great Dane, greyhound, leonberger, German pinscher, rottweiler, shar pei, toy poodle, West Highland white terrier, and whippet). The ascitic fluids were classified as follows: 10 as transudates resulting from decreased COP, 18 as transudates resulting from increased hydrostatic pressure, 13 as exudates, and 29 as hemorrhagic. The underlying causes for ascites formation are summarized in Table 1.

**Ascitic Fluid TP, Hematocrit, and TNCC Analysis**

The hematological and ascitic fluid characteristics of the dogs included in the study are summarized in Table 2. As expected, all transudates due to decreased COP had serum TP <4 g/dL, which is the cutoff value under which the occurrence of a vascular fluid outflow due to decreased COP has previously been suggested.15 All the increased hydrostatic pressure transudates had serum TP >4 g/dL and ascitic TP similar to the exudates, but low ascitic TNCC. The exudative ascites had the highest fluid TNCC count. Finally, the hemorrhagic ascites had a similar ascitic and peripheral TP and hematocrit, and all the ascitic hematocrit were at least >50% of the peripheral hematocrit, whereas in all the other types of effusions, the ascitic hematocrit never reached 25% of the peripheral hematocrit (data not shown).

**Ascitic Fluid and Plasma Fibrinogen, FDPs, and D-Dimer Analysis**

Ascitic fibrinogen concentrations (median = 59 mg/dL; range: 59–122 mg/dL) were significantly (P < .0001) lower than those in the plasma (median = 168 mg/dL; range: 59–879 mg/dL; Fig 1). In each dog, when the ascitic fibrinogen concentration was compared to its corresponding plasma value, the ascitic fibrinogen concentration was lower than the plasma sample in all but 1 dog, and equal in the remaining case. Ascitic fibrinogen concentrations were lower than the plasma reference interval (152–284 mg/dL) in all 70 samples, and in

---

### Table 1. Causes of ascites in 70 dogs.

| Group 1 (n = 10) | Group 2 (n = 18) | Group 3 (n = 13) | Group 4 (n = 29) |
|------------------|------------------|------------------|------------------|
| PLE (5)          | Right-sided CHF (14): Neoplasia directly involving the abdominal wall | Hemangiosarcoma (21) |
| PLN (1)          | – Neoplastic PE (5) | – or the intra-abdominal organ serosal surfaces (5) | Other malignancies (4) |
| Concurrent PLN   | – Idiopathic PE (3) | – Nonseptic peritonitis (3) | Benign tumor (1) |
| and PLE (2)      | – Myocardial, valvular, and/or arrhythmogenic diseases (6) | – Septic peritonitis (3) | Neutrophilic hepatitis (1) |
| Hepatic failure (2) | Other diseases causing portal hypertension (4) | – Bile peritonitis (2) | Iatrogenic (1) |

*Group 1: transudates due to decreased colloid osmotic pressure; Group 2: transudates due to increased hydrostatic pressure; Group 3: exudates; Group 4: hemorrhagic ascites; CHF, congestive heart failure; PLE, protein losing enteropathy; PLN, protein losing nephropathy; PE, pericardial effusion.*

### Table 2. Hematological and ascitic fluid characteristics in the 4 groups of dogs with ascites included in the study.

|                      | Group 1 (n = 10) | Group 2 (n = 18) | Group 3 (n = 13) | Group 4 (n = 29) |
|----------------------|------------------|------------------|------------------|------------------|
| Blood Hct (%)        | 41.5 (19.2–69.8) | 40.5 (14.0–67.0) | 43.8 (24.0–59.4) | 28.9 (13.4–53.2) |
| Median (range)       |                  |                  |                  |                  |
| Serum TP (g/dL)      | 3.1 (2.2–3.9)    | 5.0 (4.2–6.2)    | 6.2 (4.4–7.5)    | 5.8 (4.2–7.7)    |
| Median (range)       |                  |                  |                  |                  |
| Serum Albumin (g/dL) | 1.3 (0.9–1.4)    | 2.5 (1.4–2.8)    | 2.5 (1.8–3.1)    | 2.8 (1.5–3.8)    |
| Median (range)       |                  |                  |                  |                  |
| Ascitic Hct (%)      | 0.0 (0.0–0.1)    | 0.1 (0.0–2.2)    | 0.7 (0.2–9.4)    | 29.8 (7.9–45.8)  |
| Median (range)       |                  |                  |                  |                  |
| Ascitic TP (g/dL)    | 0.2 (0.1–0.4)    | 3.5 (0.1–5.4)    | 3.7 (1.8–5.1)    | 5.1 (3.1–8.0)    |
| Median (range)       |                  |                  |                  |                  |
| Ascitic TNCC (10^3 μL) | 0.19 (0.02–0.86) | 0.33 (0.01–1.17) | 28.06 (2.30–173.55) | 11.12 (3.10–33.80) |
| Median (range)       |                  |                  |                  |                  |

*Group 1: transudates due to decreased colloid osmotic pressure; Group 2: transudates due to increased hydrostatic pressure; Group 3: exudates; Group 4: hemorrhagic ascites; Hct, hematocrit; TP, total protein; TNCC, total nucleated cell count.*
65 of 70 ascitic fluids, the fibrinogen concentrations were under the limit of detection of the instrument (ie, <60 mg/dL). In the 5 samples with fibrinogen concentrations above the lower limit of detection, 2 measured at 60 mg/dL, and the other 3 measured 72, 104, and 122 mg/dL.

The ascites and plasma concentrations of FDPs are summarized in Table 3 for all 70 dogs. On average, the concentrations of FDPs in the ascitic fluid were significantly (P < .0001) lower than those in the plasma. In each dog, when the ascitic concentration of FDPs was compared to its corresponding plasma value, the ascitic concentration of FDPs was higher than the plasma sample in 36 cases, equal in 33 cases, and lower in 1 case. Ascitic concentrations of FDPs were higher than the plasma reference interval (<5 µg/mL) in 67 of the 70 ascitic fluids.

As with fibrinogen, the concentrations of FDPs were significantly higher in ascitic fluids than in plasma. In each dog, when the ascitic FDP concentration was compared to its corresponding plasma value, the ascitic FDP concentration was higher than the plasma sample concentration in 65 cases, lower in 4 cases, and equal in 1 case. Ascitic concentrations of FDPs were higher than the plasma reference interval (0.01–0.34 µg/mL) in 66 of the 70 ascitic fluids.

In conclusion, all the ascitic fluids had low or a non-detectable fibrinogen concentrations and at least 1 fibrin/fibrinogenolytic marker above the reference interval of what is considered normal in a plasma sample.

Table 3. Comparison of ascitic and plasma concentrations of fibrin–fibrinogen degradation products (FDPs)

| FDPs (µg/mL) | Ascites (n [%] of Dogs) | Plasma (n [%] of Dogs) |
|-------------|------------------------|------------------------|
| <5          | 3 (4.3)                | 17 (24.3)              |
| ≥5 to <20   | 10 (14.3)              | 28 (40.0)              |
| ≥20         | 57 (81.4)              | 25 (35.7)              |

Fig 1. Box-and-whisker plots of plasma and ascitic fibrinogen concentrations in samples obtained from all the 70 dogs included in the study. Ascitic fibrinogen concentrations (median = 59 mg/dL; range: 59–60 mg/dL) were significantly (P < .0001) lower than plasma fibrinogen concentrations (median = 168 mg/dL; range: 59–879 mg/dL). For each box, the horizontal line represents the median value and lower, and upper boundaries represent 25th and 75th percentiles, respectively. Whiskers represent the most extreme observation that are not outliers. White circles represent outlier values (more than 1.5 interquartile range away from the closest end of the box), and black stars represent extreme outlier values (more than 3 interquartile range away from the closest end of the box).

Fig 2. Box-and-whisker plots of plasma and ascitic D-dimer concentrations in samples obtained from all the 70 dogs included in the study. Ascitic D-dimer concentrations were significantly (P < .0001) higher (median: 3.98 µg/mL; range: 0.02–9.19) than plasma D-dimer concentrations (median: 0.11 µg/mL; range: 0.01–4.08). For each box, the horizontal line represents the median value, and lower and upper boundaries represent 25th and 75th percentiles, respectively. Whiskers represent the most extreme observation that are not outliers. White circles represent outlier values (more than 1.5 interquartile range away from the closest end of the box), and black stars represent extreme outlier values (more than 3 interquartile range away from the closest end of the box).

46 Zoia et al
plasma concentrations in all the 4 groups. However, this difference did not reach statistical significance in group 1 (decreased COP) (Table 4).

Finally, there was a significant ($P = .001$) weak positive correlation ($p = 0.39$) between ascitic TP and ascitic D-dimer.

### Discussion

In this cross-sectional study, we investigated whether coagulation and fibrinogenolytic/fibrinolytic activity occurs in any type of canine ascitic fluid. The results show that (1) in the ascitic fluid of dogs, there is evidence of coagulation activation and fibrinolysis in almost all cases, and (2) this phenomenon occurs independent of the underlying mechanism that leads to ascites formation.

The first statement is supported by the finding that fibrinogen concentrations in dogs are significantly lower (and most of the time undetectable) in the ascitic fluid, compared to plasma, whereas FDPs and D-dimer ascitic concentrations are significantly higher than those in the plasma. All together, these results would suggest that fibrinogen, upon entrance into the abdominal cavity, is transformed into cross-linked fibrin and then lysed to form D-dimer. The increased FDPs would support this finding, but also suggests that some fibrinogen fibrin monomer or polymers may get lysed even before being transformed in cross-linked fibrin. The same conclusion has been reported in human medicine.3–7

To assess whether the fibrinogenolytic/fibrinolytic activity of the ascitic fluid depends on the type of abdominal effusions, the data were also analyzed categorizing the abdominal fluids according to their pathophysiology of formation (ie, transudates due to decreased COP, transudates due to increased hydrostatic pressure, exudates, and hemorrhagic ascites). In all of the 4 groups, ascitic fibrinogen concentrations were significantly lower than were the plasma fibrinogen concentrations, whereas the D-dimer ascitic concentrations were significantly higher than the plasma D-dimer concentrations. This further suggests that the fibrinogen, with the aid of the proteins involved in coagulation, is transformed to cross-linked fibrin upon entrance into the abdominal cavity and is then lysed to FDPs and D-dimer, regardless of the pathophysiology of fluid formation. Also, the concentrations of the FDPs in the ascites were higher than were their respective plasma concentrations in all of the 4 groups. However, this difference did not reach statistical significance in group 1. While it is possible that there was really no significant difference between plasma and ascites FDPs' concentrations in group 1, 3 alternative explanations should be also considered. First, group 1 includes a small number of dogs, limiting the statistical power to recognize small differences between concentrations of FDPs in the

| Parameter | Ascites | Plasma | $P$ Value |
|-----------|---------|--------|-----------|
| Fibrinogen (mg/dL) | Median (range) | 59 (59–59) | 344 (79–774) | .005 |
| D-dimer (µg/mL) | Median (range) | 1.68 (0.44–5.65) | 0.05 (0.01–0.72) | .005 |
| FDPs (µg/mL) | Median (range) | <5 | n = 2 | n = 7 |
| | | ≥5 to <20 | n = 5 | n = 2 |
| | | ≥20 | n = 3 | n = 1 |
| Fibrinogen (mg/dL) | Median (range) | 59 (59–72) | 164 (60–678) | <.0001 |
| D-dimer (µg/mL) | Median (range) | 2.55 (0.29–9.19) | 0.05 (0.01–0.78) | <.0001 |
| FDPs (µg/mL) | Median (range) | <5 | n = 1 | n = 1 |
| | | ≥5 to <20 | n = 2 | n = 14 |
| | | ≥20 | n = 15 | n = 3 |
| Fibrinogen (mg/dL) | Median (range) | 59 (59–122) | 327 (59–879) | .002 |
| D-dimer (µg/mL) | Median (range) | 6.79 (0.02–8.71) | 0.15 (0.01–2.76) | .006 |
| FDPs (µg/mL) | Median (range) | <5 | n = 0 | n = 3 |
| | | ≥5 to <20 | n = 0 | n = 2 |
| | | ≥20 | n = 13 | n = 8 |
| Fibrinogen (mg/dL) | Median (range) | 59 (59–59) | 157 (60–459) | <.0001 |
| D-dimer (µg/mL) | Median (range) | 5.86 (0.10–9.05) | 0.26 (0.01–4.08) | <.0001 |
| FDPs (µg/mL) | Median (range) | <5 | n = 0 | n = 6 |
| | | ≥5 to <20 | n = 3 | n = 10 |
| | | ≥20 | n = 26 | n = 13 |

Group 1: transudates due to decreased colloid osmotic pressure; Group 2: transudates due to increased hydrostatic pressure; Group 3: exudates; Group 4: hemorrhagic ascites; FDPs, fibrin–fibrinogen degradation products.
ascites and plasma. Second, in the assay that was used concentrations of FDPs are expressed semiquantitatively, limiting the possibility of assessing the magnitude of FDPs' concentrations between ≥25 and <20 and ≥20 µg/mL which are FDPs values more frequently present in the ascites rather than the plasma. Third, as shown from the positive correlation between ascitic TP and ascitic D-dimer, it appears that a lower ascitic TP concentration corresponds with a lower ascitic D-dimer.

This could also suggest that the fibrinogen and other clotting proteins in the ascites of group 1 was in small concentrations, even before being transformed in cross-linked fibrin and then in D-dimer. Therefore, the lower FDPs and D-dimer in group 1, and the lack of statistical difference between ascitic and plasma FDPs in this type of ascites fluid, more likely represent a decreased fibrin formation due to an originally low fibrinogen concentration rather than a decreased fibrinolytic activity in this fluid. In addition, a possible low fibrinogen concentration, the lower FDPs and D-dimer in group 1 may also be caused by a lower concentration of plasminogen activators, plasmin, or plasmin-like factors in this type of ascitic fluid.

The results of this study, suggesting that the activation of coagulation followed by fibrinolysis occurs in ascitic fluids regardless of the pathophysiology of fluid formation, are in agreement with 1 study in horses, 6,7 and 2 studies in humans with ascites. 6,7 In the study in horses it has been demonstrated that ascitic fibrinogen generation is significantly (10 times) higher than its concentration in plasma. This result was considered consistent with peritoneal hyperfibrinolysis by the authors. 6 In the 2 studies in humans, 25 patients with portal hypertension and ascites secondary to liver cirrhosis were enrolled, in addition to 10 patients with ascites but without liver diseases. As in the dogs of this study, all 35 human patients with ascites had concentration of FDPs and D-dimer in the ascitic fluid that, for the plasma, would be considered quite high. 6,7 Fibrinogen concentrations were depleted both in horses that, for plasma, would be considered quite normal. 6,7 The fibrinogen concentrations in these studies concluded that any abdominal fluid should be considered inherently fibrinolytic and a possible contributor for the systemic increased fibrinogenolytic/fibrinolytic activity present in the subset of patients with ascites secondary to portal hypertension due to liver cirrhosis. 6,7

The hypothesis that ascitic fluid is inherently fibrinolytic is also supported by several observations/pieces of evidence. First, the fluid of virtual cavities, of which ascites is a pathological manifestation, needs to be free of clots to allow for smooth sliding of organs over each other, and therefore, clots need to be rapidly lysed. Second, the hypothesis is supported by the clinical observation that ascites and pleural fluid are rarely formed in vivo. This observation is confirmed by an experiment in dogs in which the inoculation of blood or of a solution containing fibrinogen and thrombin into the pleural cavity caused the activation of the coagulation system followed by a rapid fibrinogenolytic/fibrinolysis, allowing to the inoculated blood to remain in the large part fluid. 16 These early findings have been later confirmed by another experimental study in dogs. 17 And by clinical studies in humans with hemothorax. 18,19

Similar results have also been found after the inoculation of blood in the peritoneal cavity of dogs, which remains in the large part fluid unless these dogs were pretreated by continuous infusion with epsilon-aminocaproic acid (an antifibrinolytic drug) before and during the experiment. 20 Third, a study of 23 plasma proteins revealed that only fibrinogen and plasminogen had a lower concentration than expected in the ascitic fluid, suggesting an accelerated degradation of these proteins in plasmin and FDPs after the activation of the fibrinolytic system within this fluid. 5 The activation of the plasminogen in the ascitic fluid is due to the presence of tissue plasminogen activator, urinary plasminogen activator, or both enzymes which can be released (from a preformed storage pool) or leak in the ascitic fluid (following the damage induced by the disease causing the ascites formation) from the mesothelial and submesothelial endothelium cells. 5,21–27 Ultimately, in support of the fibrinolytic activity of the ascitic fluid, there is also the evidence of primary hyperfibrinolysis in ascitic human patients treated with palliative peritoneovenous shunts after the reinfusion of their abdominal fluid in the systemic circulation. 23,26,28–30

Primary hyperfibrinolysis, also sometimes named primary hyperfibrinogenolysis, 31,32 is a rare condition that occurs when the generation of plasmin within the general circulation (plasminemia) overwhelms the neutralizing capacity of the antiplasmins. 33 In humans, this has been reported in association with acute conditions, such as shock, 31,34 surgical procedures, 34 liver transplantation, 35 acute leukemia, 36 or the administration of thrombolytic drugs. It can also be caused by chronic conditions such as neoplasia, 37 chronic liver disease, 38 or, as said before, after peritoneovenous shunting 23,26,28–30. Recently, it has been demonstrated that 90% of dogs with ascites secondary to right-sided CHF have abnormalities in their coagulation tests, suggesting primary hyperfibrinolysis (PHF). 39 The prevalence of PHF in dogs with right-sided CHF was significantly higher compared to what found in dogs with left-sided CHF and in sick dogs without cardiac diseases, suggesting a primary role for the ascites in this coagulation disorder. 39 The results of this study, which show that ascitic fluids have fibrinolytic activity, may support the hypothesis that the observed PHF described in dogs with ascites secondary to right-sided CHF may have possibly been caused by the reabsorption of their ascitic fluid containing plasminogen activator, plasmin, or plasmin-like factors. Whether this is true, or if other mechanisms for the observed PHF are also present, needs to be explored in further studies.

One limitation of this study is that ascitic fibrinogen, FDPs, and D-dimer concentrations were measured with kits that had been validated only in canine plasma samples and not in canine ascitic samples. Nevertheless, the 2 human studies and the 1 study in horses to which this article refers also adopted the same methodology without apparent problems. 6,7 A second limitation of this study is that the ascitic
concentrations of tissue plasminogen activator, urinary plasminogen activator, and plasmin were not measured. The determination of these enzymes would have strengthened our findings.

In summary, this study shows that ascitic fluid has fibrinogenolytic/fibrinolytic activity, independent of the underlying mechanism of intra-abdominal fluid accumulation. This result, together with the observation that most dogs with ascites secondary to right-sided CHF have coagulation tests that suggest PHF,39 should encourage further studies to ascertain whether or not fibrinolytic ascitic fluid is associated with PHF in dogs.

Footnotes

a. Olympus AU 2700, Olympus Diagnostics, Hamburg, Germany
b. 3.2% sodium citrate Vacuette® 3.5 mL, Grenier Bio-One, Kremsmünster, Austria
c. STA Fibringen, Diagnostica Stago, Asnières sur Seine, France
d. STA-R Evolution, Diagnostica Stago, Roche, Basel, Switzerland
e. FDPs plasma, Diagnostica Stago, Asnières sur Seine, France
f. Caldin M, Furlanello T, Lubas G. Sensitivity and specificity of citrated plasma FDPs and D-dimer in the diagnosis of disseminated intravascular coagulation (DIC) in dogs. J Vet Intern Med 1998;12:236 (abstract)
g. Tina-quant D-Dimer, Roche Diagnostic GmbH, Mannheim, Germany

Acknowledgments

Conflict of Interest Declaration: Authors declare no conflict of interest.

Off-label Antimicrobial Declaration: Authors declare no off-label use of antimicrobials.

References

1. Burgess LJ. Biochemical analysis of pleural, peritoneal and pericardial effusions. Clin Chim Acta 2004;343:61–84.
2. Krath S. Abdominal distension, ascites and peritonitis. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine, 6th ed. St. Louis, MO: Elsevier Saunders; 2005:150–153.
3. Runyon BA, Montano AA, Akrividas EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992;117:215–220.
4. Kopcinovic LM, Culej J. Pleural, peritoneal and pericardial effusions—A biochemical approach. Biochem Med 2014;24:123–137.
5. Henderson JM, Stein SF, Kutner M, et al. Analysis of twenty-three plasma proteins in ascites. The depletion of fibrinogen and plasminogen. Ann Surg 1980;192:738–743.
6. Agarwal S, Joyner KA, Swaim MW. Ascites as a possible origin for hyperfibrinolysis in advanced liver disease. Am J Gastroenterol 2000;95:3218–3224.
7. Diab SM, Fathy EM, Soliman HH, et al. Hyperfibrinolysis in advanced liver disease: Does ascites have a role? Arab J Gastro 2005;6:124–130.
8. Delgado MA, Monreal L, Armengou L, et al. Peritoneal D-dimer concentration for assessing peritoneal fibrinolytic activity in horses with colic. J Vet Intern Med 2009;23:882–889.
9. Rose BD, Post TW. Edematous states. In: Rose BD, Post TW, eds. Clinical Physiology of Acid-base and Electrolyte Disorders. New York, NY: McGraw-Hill; 2001:478–534.
10. Grootendorst AF, Wilgenberg MGM, de Laat PHJM, et al. Albumin abuse in intensive care medicine. Intensive Care Med 1988;14:554–557.
11. Gabel JC, Scott RL, Adair TH, et al. Errors in calculated oncotic pressure of dog plasma. Am J Physiol 1980;239:H810–H812.
12. Navar PD, Narar LG. Relationship between colloid osmotic pressure and plasma protein concentration in the dog. Am J Physiol 1977;239:H810–H812.
13. Stokol T, Brooks M, Erb H, et al. Evaluation of kits for the detection of fibrinogen degradation products in dogs. J Vet Intern Med 1999;13:478–484.
14. Caldin M, Furlanello T, Lubas G. Validation of an immunoturbidimetric D-dimer assay in canine citrated plasma. Vet Clin Pathol 2000;29:51–54.
15. Tobias TA, Schertel ER. Shock: Concepts and management. In: DiBartola SP, ed. Fluid Therapy in Small Animal Practice, Philadelphia, PA: WB Saunders Co; 1992:436–470.
16. Denny GP, Minot GR. The coagulation of blood in the pleural cavity. Am J Physiol 1916;39:455–458.
17. Napoli VM, Symbas PJ, Vroon DH, et al. Autotransfusion from experimental hemothorax: Levels of coagulation factors. J Trauma 1987;27:296–300.
18. Broadie TA, Glover JL, Bang N, et al. Clotting competence of intraabdominal blood in trauma victims. Ann Emerg Med 1981;10:127–130.
19. Schved JF, Gris JC, Gilly D, et al. Fibrinolytic activity in traumatic hemothorax fluids. Ann Fr Anesthes Reanim 1991;10:104–107.
20. Moore KL, Bang NU, Broadie TA, et al. Peritoneal fibrinolysis: Evidence for the efficiency of the tissue-type plasminogen activator. J Lab Clin Med 1983;101:921–929.
21. van Goor H, Bom VJ, van der Meer J, et al. Coagulation and fibrinolytic responses of human peritoneal fluid and plasma to bacterial peritonitis. Br J Surg 1996;83:1133–1135.
22. Holmdahl L, Eriksson E, Al-Jabreen M, et al. Fibrinolysis in human peritonem during operation. Surgery 1996;119:701–705.
23. Scottcoombes DM, Whawell SA, Vipond MN, et al. Fibrinolytic activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy. Gut 1993;34:1120–1123.
24. Huber K, Wojta J, Kirchheimer JC, et al. Plasminogen activators and plasminogen activator inhibitor in malignant and nonmalignant ascitic fluid. Eur J Clin Invest 1988;18:595–599.
25. Vipond MN, Whawell SA, Dudley HAF, et al. Peritoneal fibrinolytic activity and intra-abdominal adhesions. Lancet 1990;335:1120–1122.
26. Schölmerich J, Zimmermann U, Köttgen E, et al. Proteases and antiproteases related to the coagulation system in plasma and ascites. Prediction of coagulation disorder in ascites retransfusion. J Hepatol 1988;6:359–363.
27. Wilde JT, Cooper P, Kennedy HJ, et al. Coagulation disturbances following asites reirfusion. J Hepatol 1990;10:217–222.
28. Patrassi GM, Martinielli S, Sturniolo GC, et al. Fibrinolytic study in plasma and ascitic fluid of cirrhotic patients before and after ascites concentration; reinfusion technique. Eur J Clin Invest 1985;15:161–165.
29. Greig PD, Langer B, Blendis LM, et al. Complications after peritoneovenous shunting for ascites. Am J Surg 1980;139:125–131.
30. Lévy VG, Opolon P, Pauleau N, et al. Treatment of ascites by reinfusion of concentrated peritoneal fluid: Review of 318 procedures in 210 patients. Postgrad Med J 1975;51:564–566.
31. Mazzi G, Raineri A, Lacava E, et al. Primary hyperfibrinogenolysis in a patient with anaphylactic shock. Haematologica 1994;79:283–285.
32. Sallah S, Gagnon GA. Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel. Cancer Invest 2000;18:191–196.
33. Rodgers GM. Acquired coagulation disorders. In: Greer JP, Arber DA, Glader B, List AF, Means RT Jr, Paraskevas F, Rodgers GM, eds. Wintrobe’s Clinical Hematology, 13th ed. Philadelphia, PA: Wolters Kluwer Lippincott Williams and Wilkins Health; 2014:1186–1217.
34. von Sommoggy S, Fraunhofer S, Wahba A, et al. Coagulation in aortofemoral bifurcation bypass grafting. Eur J Vasc Surg 1991;5:247–253.
35. Blankensteijn JD, Schalm SW, Terpstra OT. New aspects of heterotopic liver transplantation. Transpl Int 1992;5:43–50.
36. García Frade LJ, Sureda A, Torrado MC, et al. High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia. Acta Haematol 1992;88:7–10.
37. Okajima K, Kohno I, Tsuruta J, et al. Direct evidence for systemic fibrinogenolysis in a patient with metastatic prostatic cancer. Thromb Res 1992;66:717–727.
38. Violi F, Ferro D, Basili S, et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation abnormalities in liver cirrhosis. Hepatology 1993;17:78–83.
39. Zoía A, Augusto M, Drigo M, et al. Evaluation of hemostatic and fibrinolytic markers in dogs with ascites attributable to right-sided congestive heart failure. J Am Vet Med Assoc 2012;241:1336–1343.